Stock Report

All about this stock under one free report Last Updated: 14-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All
  • Homearrow
  • Stocksarrow
  • Clarus Therapeutics Holdings Inc. (CRXT)

Clarus Therapeutics Holdings Inc. (CRXT)

Stock Card factsheet share-fund-plan-icon

$0.02

up-down-arrow $-0.01 (-19.54%)

As on 08-Nov-2022 09:30EDT

Market cap

info icon

$2 Mln

Revenue (TTM)

info icon

$19 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0

Div. Yield

info icon

0 %

Clarus Therapeutics Holdings (CRXT) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading

Max:loading Min:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.02 High: 0.03

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $-32 Mln

  • ROEROE information

    0 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    26.75

  • EV/EBITDAEV/EBITDA information

    -1

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $--

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    52,020,700

10 Years Aggregate

CFO

$-142.49 Mln

EBITDA

$-4.94 Mln

Net Profit

$-36.27 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Clarus Therapeutics Holdings (CRXT)
-99.1 -46.8 -93.1 -99.6 -- -- --
BSE Sensex*
-11.0 -1.9 -8.7 -7.1 6.7 9.1 11.5
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 08-Nov-2022  |  *As on 14-May-2026  |  #As on 26-Oct-2023
The underlying data is unavailable.

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Clarus Therapeutics Holdings (CRXT)

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate...  for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.  Read more

  • Founder, Pres, CEO & Director

    Dr. Robert E. Dudley Ph.D.

  • Founder, Pres, CEO & Director

    Dr. Robert E. Dudley Ph.D.

  • Headquarters

    Northbrook, IL

  • Website

    https://clarustherapeutics.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Clarus Therapeutics Holdings (CRXT)

The share price of Clarus Therapeutics Holdings Inc (CRXT) is $0.02 (NASDAQ) as of 08-Nov-2022 09:30 EDT. Clarus Therapeutics Holdings Inc (CRXT) has given a return of -99.59% in the last 1 years.

Since, TTM earnings of Clarus Therapeutics Holdings Inc (CRXT) is negative, P/E ratio is not available.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2021
--
--
2020
--
--
2019
--
--
2013
--
--
2012
--
--

The 52-week high and low of Clarus Therapeutics Holdings Inc (CRXT) are Rs -- and Rs -- as of 14-May-2026.

Clarus Therapeutics Holdings Inc (CRXT) has a market capitalisation of $ 2 Mln as on 08-Nov-2022. As per SEBI classification, it is a Small Cap company.

Before investing in Clarus Therapeutics Holdings Inc (CRXT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.